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Objective: to investigate the incidence and risk factors for renal function deterioration after renal angiography and
angioplasty or stenting.
Methods: a retrospective study of 85 consecutive patients undergoing selective renal artery arteriography (n 53) or renal
artery angioplasty % (PTRA) stenting (n 32) for renal artery stenosis. Multivariate logistic regression analysis was used
to determine independent predictors of deterioration of renal function, defined as an increase of serum creatinine by at least
one third within 24 h.
Results: deterioration of renal function occurred in 13 patients (15%), [8/53 (15%) after angiography and 5/32 (16%) after
PTRA/stenting]. Only pre-existing renal impairment (se-creatinine 177mmol/l) (Odds ratio: 40; 95% confidence interval
1.2±72, p 0.02) and administered dosage of contrast agent (more than 225 ml) (OR 67; 95% CI1 1.8±100, p 0.02) were
independently associated with renal function deterioration.
Conclusion: transient renal dysfunction after renal artery angiography or PTRA/stenting occurs in about 15% of patients,
but persistent renal failure is uncommon. Pre-existing renal impairment and amount of contrast agent are independent risk
factors. Endovascular treatment of renal artery stenosis is not associated with a higher risk of renal deterioration compared
to selective renal angiography.
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Hypertension and chronic renal failure due to renal
artery stenosis (RAS) can be treated successfully by
renal artery angioplasty on stenting.1±9 However, many
patients with RAS already have impaired renal func-
tion which may be calculated by renal angiography.10±22
Micro-embolisation into the kidney during the
angioplasty has led some authors to recommend the
use of endovascular protection devices.23 However,
the rate of renal impairment in patients undergoing
selective renal artery angiography vs endovascular
renal artery revascularisation has not been compared
yet. The aim of the present study was to investigate
how often renal function deteriorated in patients after
angiography with and without subsequent angio-
plasty and to assess independent risk factors for the
occurrence of renal function reduction.Please address all correspondence to: E. Minar, University of
Vienna, Department of Angiology, Vienna General Hospital,
WaÈhringer GuÈ rtel 18±20, A-1090 Vienna, Austria.
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All consecutive patients with renal artery stenosis
who underwent selective renal artery angiography
and who were planned for subsequent renal artery
PTA from March 1, 1988 until September 31, 2000 at
the Department of Angiology entered a retrospective
survey. All patients in the intervention group and in
the angiography group underwent selective renal
angiography of both renal arteries. Patients who
underwent overview angiography of the renal arteries
during angiographic procedures in the abdominal
aorta or in the lower limbs were excluded. The study
was performed according to the Declaration of
Helsinki.
Patients were identified by systematic chart review
and review of the original angiography and PTA
protocols. Following a strict protocol, angiography/
PTRA were performed in patients with drug resistant
arterial hypertension (more than 3 antihypertensive
agents), pathological isotopic nephroscintigram and
haemodynamically relevant renal artery stenosis
documented by colour-coded duplexsonographyl rights reserved.
Renal Artery PTA 157as well as in patients with suspicion of ischaemic
nephropathy indicated by progressive reduction of
renal function parameters in conjunction with steno-
tic flow pattern of the renal arteries in duplex sono-
graphy. The final indication for PTRA was a renal
artery stenosis with more than 50% lumen narrowing.
Stent implantation was performed in cases of resi-
dual stenosis >30% after primary dilatation or in
cases of vessel dissection. Renal artery stenosis in
vessels of shrunken kidneys were not eligible for
PTRA. Shrunken kidneys was defined as reduced
maximum diameter of at least 3 cm compared to the
contralateral kidney. All angiographic procedures
and interventions at our department are systema-
tically recorded in an angiography/PTA registry.
Findings of pre-interventional duplex sonography,
angiographic data and PTA success were regis-
tered. Procedural complications and the post-
procedural need for haemodialysis were documented
routinely.
Hydration in patients with normal renal function
was checked clinically by the physician in charge by
aspects of the mucosa and skin. Patients with clinical
suspicion of dehydration and patients with base-
line serum creatinine levels 124 mmol/l routinely
received extra fluids intravenously peri-interventional
as a protective strategy. Throughout the whole obser-
vation period the non-ionic, low-osmolality contrast
agent Optiray 320, Tyco diluted to equal amount
of physiological saline solution. Baseline serum
creatinine, complete blood count and coagulation
parameters were obtained in all patients before PTA.
Serum creatinine was measured routinely 24 h after
the intervention. In patients with an increase of
serum creatinine of at least one third and in patients
with a serum creatinine 124 mmol/l at 24 h, creatinine
values were obtained also at 48 h postintervention. All
85 patients had baseline and 24 h serum creatinine
data available, in 27 patients (32%) serum creatinine
was additionally measured 48 h after the intervention.
Pre-existent impaired renal function was defined
as a serum creatinine 177 mmol/l at admission.24
Deterioration of renal function was defined as an
increase of serum creatinine of at least one third
from baseline within 24 h after the procedure.17,29 Pro-
cedure complications were classified as either major
complications (acute thrombotic renal artery occlusion
after the procedure, major bleeding with a decrease
of haemoglobin4 20 g/l, persistent renal failure post-
procedure and complications at the site of arterial
puncture requiring surgical repair) or minor compli-
cations (dissection of the intima of the renal artery
during PTA, mild and transient renal failure not
requiring haemodialysis and local false aneurysms orhaematoma at the site of arterial puncture, which were
treated conservatively).
Statistical methods
Continuous data are presented as the median and the
interquartile range (IQR, range from the 25th to the
75th percentile). Percentages were calculated for
dichotomous data. The relative change of serum crea-
tinine within 24 h post-procedure was calculated.
Patients were then dichotomised according to a cut-
off level of 1/3 of serum creatinine increase. The
Chi-square test was applied to compare proportions.
The Mann±Whitney U-test was used to compare conti-
nuous data. A multivariate logistic regression model
was applied to assess independent predictors of renal
function reduction and to adjust for confounding
factors. Baseline variables that showed a trend
towards a difference (p5 0.2) were entered into the
model as possible confounding factors. The Hosmer
Lemeshow test was used to assess the model fit. All
p-values were calculated two-sided, a p-value5 0.05
was accepted as statistically significant. All calcula-
tions were performed with SPSS for Windows
(Version 10.0, SPSS Inc., Chicago, Ill, U.S.A.).
Results
Eighty-five consecutive patients were included in the
study. The median age was 65 years (IQR 54±74) and
49 patients were male (51%). Patients demographics
and baseline data are given in Table 1.
Diagnostic bilateral renal angiography was
performed in 53 (62%) patients and 32 (38%) had
patients had balloon angioplasty ± in half using a
stent (Table 1). Intervention was performed immedi-
ately after angiography in 28 (88%) cases; in 4 during a
second procedure. Two patients (4%) out of the PTRA
group had an occluded contralateral renal artery,
2 patients (4%) showed a contralateral shrunken
kidney and another 2 patients (4%) underwent
contralateral nephrectomy earlier. Duration of the pro-
cedure and the amount of contrast agent is given in
Table 1. Peri-procedural complications were observed
in 9 patients (11%): 3 patients had persistent renal
failure, 3 patients had a pseudo-aneurysm at the
site of arterial puncture, 1 patient had an acute throm-
botic renal artery occlusion, 1 patient suffered peri-
interventional angina pectoris, and 1 patient had a
vasovagal reaction with transient hypotension.
Baseline creatinine was 106 mmol/l (IQR 87±136).
Twenty-four hours after the procedure medianEur J Vasc Endovasc Surg Vol 24, August 2002
Table 1. Comparison of patients who had renal artery arteriography alone and patients who also had angioplasty. Median value








Age 64 (54±75) 65 (54±74) 0.7
Male sex (%) 17 (20%) 29 (34%) 1.0
Body mass index kg/m2 25 (23±28) 26 (23±28) 1.0
Diabetes mellitus (%) 8 (9%) 17 (20%) 0.8
Current smokers (%) 11 (13%) 23 (27%) 0.7
Arterial hypertension (%) 27 (32%) 51 (60%) 0.4
Hyperlipidaemia (%) 24 (28%) 47 (55%) 0.4
Cerebral artery disease (%) 21 (25%) 25 (29%) 0.05
Coronary heart disease (%) 12 (14%) 19 (22%) 0.7
Peripheral artery disease (%) 17 (20%) 36 (42%) 0.4
Pre-existing renal failure (%)
(se-creatinine  177mmol/l)
4 (5%) 4 (5%) 0.3
Creatinine serum level at baseline 1.3 (1.0±1.8) 1.1 (1.0±1.5) 0.1
Grade of stenosis in % luminal narrowing 80 (80±90) 30 (30±50) 50.0001
PTA (%) 32 (100%) 0 ±
Stent implantation 16 (50%) 0 ±
Amount of contrast agent per ml 250 (198±280) 220 (141±270) 0.3
Duration of fluoroscopy min (IQR) 13 (9±22) 9 (3±14) 0.02
Renal function reduction
(se-creatinine increase by >33%) within 24 h
5 (16%) 8 (15%) 0.9
Diabetes mellitus: HbA1c level4 6.5%, pathological oral glucose tolerance tests or as fasting blood glucose values4 6.1 mmol/l measured
3 times. Hyperlipidaemia: total serum cholesterol levels4 5.4 mmol/l, serum low density lipoprotein4 3.4 mmol/l or serum triglycerides
4 2.1 mmol/l after overnight fasting, and all patients receiving lipid lowering medication.
158 S. Sabeti et al.creatinine was 111 mmol/l (IQR 88±148) in the 85
patients. After 48 h, the serum creatinine level was
available in 27 patients (32%) and was median
117 mmol/l (IQR 103±193). In 13 (15%) patients serum
creatinine increased by  33% within the
first 24 h: 10 patients had a mild deterioration of
renal function, and 3 patients developed persistent
deterioration of renal function [(2/32 (6%) after
PTRA/stenting and 1/53 (2%) after angiography].
All three patients had compromised renal function
before the procedure, with pre-procedural creatinine
levels of 203 mmol/l, 185 mmol/l and 433 mmol/l and
two patients subsequently required haemodialysis.
Univariate comparison of patients with and without
renal function reduction is presented in Table 2.
Patients with renal function reduction were more fre-
quently male, had pre-existent renal impaired, had a
longer lasting fluoroscopy and received larger
amounts of contrast agent. The rate of renal function
reduction was equal in patients who had angiography
alone and patients who had angioplasty in addition
(Table 1).
A multivariate logistic regression model was
applied to assess independent risk factors of renal
function reduction and to adjust for confounding
factors (Table 3). Pre-existent renal impairment and
dosage of administered contrast agent were indepen-
dent predictors of renal function reduction. PatientsEur J Vasc Endovasc Surg Vol 24, August 2002undergoing PTRA/stenting did not have an increased
risk for renal function reduction compared to patients
undergoing diagnostic selective renal artery angio-
graphy without intervention (Table 3).
Discussion
Pre-existent renal dysfunction and increasing
amounts of contrast agent were independent risk
factors for acute renal dysfunction in patients under-
going selective renal artery angiography or endovas-
cular treatment of RAS.25 Pre-existent moderate renal
impairment was found in 13% in this patient series,
but chronic deteriorated renal function was not pre-
sent in any patient, since patients with irreversible
reduction of renal function and shrunken kidney
were not eligible for renal artery PTA.26±32 At our
department, the indication for PTA was set restric-
tively and revascularisation was only performed in
patients with significant renovascular stenosis (>50%)
presenting with severe hypertension (resistant to more
than 3 antihypertensive drugs) and/or incipient and
progressive renal dysfunction. This strategy is
reflected in the low number of renal artery interven-
tions performed at our institution during the study
period. However, since endovascular treatment of
patients with RAS and secondary hypertension by
Table 2. Univariate comparison of patients with or without acute renal function reduction (defined as an increase of serum creatinine of
at least one third from baseline value within 24 h) after renal artery angiography and renal artery PTA. Median value (Interquartile








Age 65 (55±73) 72 (54±76) 0.1
Male sex (%) 36 (49%) 11 (84 %) 0.03
Body mass index kg/m2 25 (23±28) 27 (25±29) 0.2
Diabetes mellitus (%) 17 (24%) 7 (54%) 0.4
Current smokers (%) 28 (39%) 3 (23%) 0.4
Arterial hypertension (%) 72 (100%) 13 (100%) 1.0
Hyperlipidaemia (%) 60 (83%) 12 (92 %) 0.7
Carotid plaques/stenosis (%) 41 (57%) 7 (54%) 1.0
Coronary artery disease (%) 27 (38%) 4 (31%) 0.5
Peripheral artery disease (%) 49 (68%) 6 (46%) 0.2
Pre-existing renal failure (%)
(se-creatinine 177mmol/l)
6 (8%) 5 (39%) 0.01
Baseline serum creatinine mmol/l 106 (88±132) 115 (88±185) 0.2
PTA (%) 27 (38%) 5 (42%) 0.8
Stent implantation (%) 11 (22%) 5 (56%) 0.1
Amount of contrast agent per ml 220 (171±270) 280 (255±300) 0.008
Duration of fluoroscopy min 10 (5 to 14) 23 (8±24) 0.02
Dosage of heparin IU 5000 5000 0.8
Diabetes mellitus: HbA1c level4 6.5%, pathological oral glucose tolerance tests or as fasting blood glucose values4 6.1 mmol/l measured
3 times. Hyperlipidaemia: total serum cholesterol levels4 5.4 mmol/l, serum low density lipoprotein4 3.4 mmol/l or serum triglycerides
> 2.1 mmol/l after overnight fasting, and all patients receiving lipid lowering medication.
Table 3. Multivariate model of predictors for renal function reduc-




Age 65 year z 5.0 0.6±62.0 0.2
Male sex 3.5 0.5±26.8 0.2
Diabetes mellitus 2.4 0.5±12.7 0.3
Pre-existing renal failure (%)
(se-creatinine 177mmol/l)
40.1 1.2±71.7 0.02
Amount of contrast agent 225 ml z 67.2 1.8±98.5 0.02
Duration of fluoroscopy 10 min z 1.9 0.2±15.9 0.6
Angioplasty stenting 0.4 0.2±3.0 0.3
Compared to selective renal angiography; zCut-off according to
the median value.
Renal Artery PTA 159angioplasty seems to have little advantage over
antihypertensive drug therapy a rather conservative
approach to renal revascularisation may be
preferable.32
In our series, transient deterioration of renal func-
tion was found in 15% of patients. Application of
contrast agent directly into the renal artery seems to
result in increased nephrotoxicity, probably due to
higher concentrations of contrast agent directly reach-
ing the kidney.18,33,34 However, angioplasty or stenting
by themselves was not associated with an increased
risk of renal deterioration. Although microembolism
reportedly occurs during the angioplasty procedure,23
these microemboli seem to be clinically well toleratedby a kidney with primarily normal function. However,
there may be other explanations for our findings: On
the one hand patients in the diagnostic angiographic
group underwent selective angiography which is
connected to renal artery catheterisation. This mani-
pulation may also cause microembolism, although the
extent of microembolism after angiography is expected
to be lower compared to angioplasty. On the other
hand, the measurement of the course of serum creati-
nine may not be sensitive enough to detect the effects
of minimal embolism due to angioplasty. Renal func-
tion may significantly decrease with serum creatinine
values remaining within the normal range. However,
the course of serum creatinine is a practicable and
clinically relevant study end point which also has
been applied to patients with femoropopliteal PTA18
as well as patients after cardiopulmonary resuscita-
tion.35 Furthermore, improvement of kidney perfusion
after successful PTRA may protect and counteract
against the injury inflicted by the use of contrast
agent and catheter manipulation at the treated
segment. In patients with pre-existing deterioration
of renal function alternatively magnetic resonance
imaging angiography36 may be performed as the first
diagnostic option for evaluation of RAS. Otherwise,
when PTA is planned in cases with confirmed RAS,
administration of contrast agent during angioplasty
has to be kept to a minimum and the use of renal
protection devices may be considered.Eur J Vasc Endovasc Surg Vol 24, August 2002
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